Peptides
TB-500 (Thymosin Beta-4)
Also called Thymosin β4 · TB500 · Thymosin Beta-4 Acetate
People seek TB-500 for stubborn tendon or muscle problems, easier movement and a return to training—often alongside BPC-157. A reliable benefit for these recovery goals has not been established in people.
Dosage & duration
One reported injected course using a product called TB-500; the peptide sequence was not verified.
One self-reported use
Reported use · unapproved regimen- Dose
- 2.5 mg per injection
- How often
- Twice weekly for 4 weeks, then once weekly
- How long
- 13 weeks in this report
That is 5 mg/week initially, then 2.5 mg/week. A personal report, not a tested or recommended regimen.
Full-length thymosin beta-4 and its short fragment are different substances. This unverified product report does not establish a dose for either one.
Why people look into it
A steadier return to activity
People look into TB-500 when tendon or muscle problems keep interrupting training. A reliable recovery benefit in people is not established.
-
Recurring discomfort
The hope is fewer setbacks from a stubborn tendon or muscle problem.
-
Easier movement
Everyday activity can matter as much as getting back to lifting or running.
-
An extra recovery tool
Some consider it alongside rehabilitation or BPC-157; added benefit remains uncertain.
What are people hoping TB-500 will do?
The goal is usually a steadier return to activity: less discomfort, easier movement and recovery from a tendon or muscle problem that keeps flaring up. Some people also ask about it when several areas hurt at once.
The research interest comes from thymosin beta-4 and related peptides involved in cell movement and wound repair. That is a reason to investigate recovery effects, not a reliable estimate of how much faster an injured person will heal.
Is it worth adding to BPC-157?
The pair is commonly discussed as a recovery stack. Adding TB-500 means another ingredient and additional cost, without a demonstrated extra benefit. In the small published knee-pain report, only four people received BPC-157 plus TB4; the study could not establish whether the combination worked better.
The familiar claim that BPC-157 handles one injury while TB-500 heals the whole body is a marketing shortcut, not a demonstrated human comparison.
What do “loading” and “maintenance” mean?
In reported schedules, these words describe a more frequent initial phase followed by less frequent use. The example above preserves one person's actual description, including its full course length. It is not evidence that everyone needs either phase.
Daily and weekly schedules both appear in discussions. The full-length peptide’s IV study does not settle the timing of other products sold as TB-500. The relative curve uses assumed timing and cannot identify an effective recovery schedule.
Why does the product name matter here?
Some sellers use TB-500 for full-length thymosin beta-4; analytical research commonly uses it for a smaller fragment, Ac-LKKTETQ. They are different substances. Before comparing an amount or study, check which one the source means.
Human research on full-length thymosin beta-4 includes IV safety studies and local eye treatments. Those findings cannot be used as proof that a similarly named vial repairs sports injuries.
How should you judge progress and trade-offs?
For an injury, look at what you can do as well as how it feels: movement, strength and tolerance of the rehabilitation workload. Feeling less pain does not by itself establish tissue repair or readiness for full training.
Benefits, long-term risks and product contents remain uncertain. FDA highlights possible immune reactions and peptide impurities; injections also introduce preparation and sterility concerns. A claim of high purity does not answer all of those questions.
Model details: TB-500 (Thymosin Beta-4) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 1.92 hours
- Absorption half-life assumed
- 0.48 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.48 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Product sequence and route are unresolved for a generic TB-500 entry.
- Do not transplant the full-length IV peak or half-life to the 7-residue fragment.
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.
Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.
tb-500-relative-timing-2026-10 · version 1
Common questions
Does TB-500 need to be injected near the injury?
No verified human comparison establishes a better recovery result from injecting near an injury. The small knee report used joint injections at a clinic; it did not compare locations or establish targeted healing from an injection under the skin.
How long before TB-500 should start helping?
There is no dependable human response deadline. Reports range from changes after several weeks to no lasting improvement. The length of a reported course is not a promise that an injury will be healed when it ends.
Are full-length TB4 and the TB-500 fragment dose-equivalent?
No dose equivalence has been established. A shared name or the same number of milligrams does not make these different peptides interchangeable.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- What people hope to notice
- Recovery discussions focus on getting back to activities limited by an injury or persistent aches.
- Common comparison
- The pairing is discussed for recovery, but adding a second peptide has not been shown to give a better result.
- Practical trade-off
- A blend adds another ingredient; the TB-500 name alone does not reliably identify which peptide it contains.
- 1. Turnock and Hearne — repair-peptide use in online communities
Original qualitative study of 493 forum threads. Supports reported recovery motivations and pairing, not clinical benefits or population prevalence.
- 2. FDA — TB-500 scientific review, July 2026
Distinguishes the Ac-LKKTETQ fragment from full thymosin beta-4; documents naming, impurity and immune-response concerns and limited clinical evidence.
- 3. Lee and Padgett — knee pain with BPC-157, with or without TB4
Retrospective report: four respondents received BPC-157 plus TB4. No randomized comparison or confirmed tissue-healing endpoint.
- 4. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.
Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.
- 5. Ruff et al. — full-length thymosin beta-4 IV study
40 healthy volunteers; IV safety and drug levels, not sports-injury recovery or the seven-residue fragment.
- 6. Rahaman et al. — TB-500 fragment and breakdown products
Original cell/rat study of Ac-LKKTETQ. A breakdown product showed a wound-assay signal; not human tendon-healing evidence.
- 7. Sosne and Ousler — thymosin beta-4 eye-drop trial
72-person dry-eye trial of a local full-length preparation; neither primary endpoint significantly differed. Does not establish injected sports-injury treatment.
- 8. Bern consensus on returning to sport after injury
General recovery interpretation: function, strength, loading and injury-specific criteria matter alongside symptoms. Not peptide-efficacy evidence.
Keep reading
Related compounds and examples
Related compounds
BPC-157
Why people consider BPC-157 for tendon, ligament, muscle and gut recovery, plus oral versus injected forms, expected timing and practical trade-offs.
TB-500 Fragment
The TB-500 fragment is a small piece of thymosin beta-4. Researchers study both the fragment and what it breaks down into; these can have different effects in laboratory experiments.
ARA-290 (Cibinetide)
ARA-290 for nerve symptoms: research doses, 28-day studies and realistic expectations for neuropathy.
Protocols featuring TB-500 (Thymosin Beta-4)
Wolverine Stack
Popular healing/repair stack pairing BPC-157 with TB-500 for soft-tissue and recovery support.
Skin GLOW Stack
Comprehensive skin-and-recovery blend (GHK-Cu + TB-500 + BPC-157 + KPV) dosed daily for collagen, healing, and anti-inflammatory support. Based on the GLOW/Upgraded-Glow blend ratios.
BPC-157 + TB-500 Healing Blend
The popular pre-mixed healing blend reconstituted as a protocol: daily BPC-157 with weekly TB-500 for soft-tissue and recovery support.